These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus. Iltz JL; Baker DE; Setter SM; Keith Campbell R Clin Ther; 2006 May; 28(5):652-65. PubMed ID: 16861088 [TBL] [Abstract][Full Text] [Related]
7. Exenatide: its position in the treatment of type 2 diabetes. Guerci B; Martin CS Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126 [TBL] [Abstract][Full Text] [Related]
8. Exenatide: a novel approach for treatment of type 2 diabetes. Mikhail N South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423 [TBL] [Abstract][Full Text] [Related]
9. A review of exenatide as adjunctive therapy in patients with type 2 diabetes. Robles GI; Singh-Franco D Drug Des Devel Ther; 2009 Sep; 3():219-40. PubMed ID: 19920937 [TBL] [Abstract][Full Text] [Related]
10. Exenatide Use in the Management of Type 2 Diabetes Mellitus. Kyriacou A; Ahmed AB Pharmaceuticals (Basel); 2010 Aug; 3(8):2554-2567. PubMed ID: 27713366 [TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults. Tzefos M; Harris K; Brackett A Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377 [TBL] [Abstract][Full Text] [Related]
12. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Parkes DG; Mace KF; Trautmann ME Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438 [TBL] [Abstract][Full Text] [Related]
13. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide. van Genugten RE; van Raalte DH; Diamant M Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus. Harris KB; McCarty DJ Ther Adv Endocrinol Metab; 2015 Feb; 6(1):3-18. PubMed ID: 25678952 [TBL] [Abstract][Full Text] [Related]
15. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Gallwitz B Int J Clin Pract; 2006 Dec; 60(12):1654-61. PubMed ID: 17109672 [TBL] [Abstract][Full Text] [Related]
16. Incretin mimetics as emerging treatments for type 2 diabetes. Joy SV; Rodgers PT; Scates AC Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141 [TBL] [Abstract][Full Text] [Related]
17. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. Martin CL Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067 [TBL] [Abstract][Full Text] [Related]
18. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Malloy J; Capparelli E; Gottschalk M; Guan X; Kothare P; Fineman M Clin Ther; 2009 Apr; 31(4):806-15. PubMed ID: 19446153 [TBL] [Abstract][Full Text] [Related]
19. Exenatide: a novel incretin mimetic agent for treating type 2 diabetes mellitus. Lam S; See S Cardiol Rev; 2006; 14(4):205-11. PubMed ID: 16788334 [TBL] [Abstract][Full Text] [Related]
20. Incretins and their role in the management of diabetes. Frias JP; Edelman SV Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]